Analysts Are Bullish on These Healthcare Stocks: Miragen Therapeutics (MGEN), Bio-Path Holdings (BPTH)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Miragen Therapeutics (MGENResearch Report), Bio-Path Holdings (BPTHResearch Report) and Sarepta Therapeutics (SRPTResearch Report) with bullish sentiments.

Miragen Therapeutics (MGEN)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Miragen Therapeutics, with a price target of $3.00. The company’s shares closed last Monday at $0.80, close to its 52-week low of $0.57.

According to TipRanks.com, Bernardino is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.5% and a 30.8% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals, Jaguar Animal Health, and Seelos Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Miragen Therapeutics with a $24.00 average price target.

See today’s analyst top recommended stocks >>

Bio-Path Holdings (BPTH)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings today and set a price target of $25.00. The company’s shares closed last Monday at $7.25, close to its 52-week low of $1.61.

According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -14.0% and a 32.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Bio-Path Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.

Sarepta Therapeutics (SRPT)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Sarepta Therapeutics, with a price target of $160.00. The company’s shares closed last Monday at $112.49.

According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -2.2% and a 44.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Precision BioSciences.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $184.91, which is a 66.6% upside from current levels. In a report issued on November 18, Citigroup also maintained a Buy rating on the stock with a $167.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.